Satellos Bioscience Inc.
MSCL.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -28.50M | -24.87M | -22.03M | -22.83M | -21.65M |
| Total Depreciation and Amortization | 4.00K | 4.00K | 13.00K | 12.00K | 14.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.00M | 2.75M | 1.93M | 4.10M | 3.92M |
| Change in Net Operating Assets | -323.00K | -1.48M | -1.47M | -1.95M | -2.39M |
| Cash from Operations | -25.82M | -23.60M | -21.55M | -20.66M | -20.10M |
| Capital Expenditure | -10.00K | -6.00K | -6.00K | -3.00K | -3.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -42.74M | -9.41M | -15.79M | 12.51M | 6.03M |
| Cash from Investing | -42.75M | -9.42M | -15.80M | 12.51M | 6.03M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 49.49M | 2.24M | 32.57M | 32.04M | 30.66M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 4.65M | -- | 6.92M | 6.92M | 6.92M |
| Cash from Financing | 54.14M | 2.24M | 39.49M | 38.96M | 37.58M |
| Foreign Exchange rate Adjustments | 414.00K | 503.00K | -197.00K | 263.00K | -467.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -14.02M | -30.27M | 1.94M | 31.07M | 23.04M |